Glenmark Pharmaceuticals Limited — Atovaquone Exporter Profile
Indian Pharmaceutical Exporter · #2 for Atovaquone · $9.3M export value · DGFT Verified
Glenmark Pharmaceuticals Limited is the #2 Indian exporter of Atovaquone with $9.3M in export value and 177 verified shipments. Glenmark Pharmaceuticals Limited holds a 0.9% market share in Atovaquone exports across 11 countries. The company exports 28 pharmaceutical products worth $205.5M across 14 therapeutic categories.
Glenmark Pharmaceuticals Limited — Atovaquone Export Profile: Buyers & Destinations
Where Does Glenmark Pharmaceuticals Limited Export Atovaquone?
| Country | Value | Shipments | Share |
|---|---|---|---|
| UNITED STATES | $4.4M | 97 | 58.7% |
| GERMANY | $1.5M | 34 | 19.4% |
| CANADA | $1.3M | 32 | 17.4% |
| UNITED ARAB EMIRATES | $100.1K | 5 | 1.3% |
| QATAR | $96.7K | 3 | 1.3% |
| SLOVENIA | $50.0K | 1 | 0.7% |
| NETHERLANDS | $47.5K | 1 | 0.6% |
| UNITED KINGDOM | $32.8K | 1 | 0.4% |
| BAHRAIN | $2.0K | 1 | 0.0% |
| ROMANIA | $731 | 8 | 0.0% |
Glenmark Pharmaceuticals Limited exports Atovaquone to 11 countries. The largest destination is UNITED STATES accounting for 58.7% of Glenmark Pharmaceuticals Limited's Atovaquone shipments, followed by GERMANY (19.4%) and CANADA (17.4%). These destinations reflect Glenmark Pharmaceuticals Limited's established distribution network and regulatory approvals in key markets.
Who Are the Top Buyers of Atovaquone from Glenmark Pharmaceuticals Limited?
| Buyer | Country | Value | Orders |
|---|---|---|---|
| GLENMARK PHARMACEUTICALS INC., USA | UNITED STATES | $2.4M | 52 |
| GLENMARK PHARMACEUTICALS CANADA INC | CANADA | $1.3M | 26 |
| GLENMARK PHARMACEUTICALS INC USA | UNITED STATES | $1.0M | 22 |
| GLENMARK PHARMACEUTICALS S.R.O. | GERMANY | $736.7K | 15 |
| CENTRAFARM SERVICES (ALLOGA NL) B.V | GERMANY | $436.4K | 10 |
| AMERISOURCE HEALTH SERVICES DBA AME | UNITED STATES | $250.0K | 5 |
| GLENMARK PHARMACEUTICALS INC, USA | UNITED STATES | $245.3K | 5 |
| NORTHSTAR DISTRIBUTION CENTER 8912 | UNITED STATES | $200.0K | 4 |
| GLENMARK PHARMACEUTICALS INC. USA | UNITED STATES | $168.6K | 4 |
| ALIUD PHARMA | GERMANY | $136.9K | 3 |
Glenmark Pharmaceuticals Limited supplies Atovaquone to 28 buyers globally. The largest buyer is GLENMARK PHARMACEUTICALS INC., USA (UNITED STATES), followed by GLENMARK PHARMACEUTICALS CANADA INC (CANADA) and GLENMARK PHARMACEUTICALS INC USA (UNITED STATES). These buyers represent pharmaceutical distributors, hospital groups, and government procurement agencies in their respective markets.
What Is India's Total Atovaquone Export Value and How Much Does Glenmark Pharmaceuticals Limited Contribute?
India exported $20.0M worth of Atovaquone through 437 shipments from 17 suppliers to 21 countries, serving 71 buyers globally. Glenmark Pharmaceuticals Limited contributes $9.3M to this total, accounting for 0.9% of India's Atovaquone exports. Glenmark Pharmaceuticals Limited ships Atovaquone to 11 countries through 28 buyers.
What Is the Average Shipment Value for Glenmark Pharmaceuticals Limited's Atovaquone Exports?
Glenmark Pharmaceuticals Limited's average Atovaquone shipment value is $52.3K per consignment, based on 177 shipments totaling $9.3M. The largest destination is UNITED STATES (58.7% of Glenmark Pharmaceuticals Limited's Atovaquone exports).
How Does Glenmark Pharmaceuticals Limited Compare to Other Indian Atovaquone Exporters?
Glenmark Pharmaceuticals Limited ranks #2 among 17 Indian Atovaquone exporters with a 0.9% market share. The top 3 exporters are GLENMARK PHARMACEUTICALS LIMITED ($8.8M), HETERO LABS LIMITED ($6.8M), MYLAN LABORATORIES LIMITED ($2.9M). Glenmark Pharmaceuticals Limited processed 177 shipments to 11 destination countries.
What Atovaquone Formulations Does Glenmark Pharmaceuticals Limited Export?
| Product Description / Formulation | Value | Shipments |
|---|---|---|
| ATOVAQUONE-PROG TAB 250/100MG 100 | $786.9K | 16 |
| ATOVAQUONE-PROG TAB 250/100MG 24UD | $700.0K | 14 |
| Atovaquone Oral Suspension 750mg/5ml CA | $500.0K | 10 |
| ATOVAQUONE-PROG TAB 250/100MG 100 Batch | $150.0K | 3 |
| ATOVAQUONE-PROG TAB 250/100MG 24UD. Batc | $150.0K | 3 |
| ATOVAQUONE OS 750MG/5ML 210ML, BATCH No. | $150.0K | 3 |
| ATOVAQUONE-PROG TAB 250/100MG 24UD (BATCH NO.19241047) | $145.3K | 3 |
| ATOVAQUONE-PROG TAB 250/100MG 24UD Batch | $133.0K | 3 |
| ATOVAQUONE PROGUANIL TAB250/100MG 12'SCFNL SNL231348C632301AZNOS | $129.1K | 3 |
| ATOVAQUONE PROGUANIL TAB250/100MG12'SCFNL SNL231348C632301AZNOS | $107.3K | 3 |
Glenmark Pharmaceuticals Limited exports 114 distinct Atovaquone formulations including tablets, capsules, syrups, and combination drugs. The top formulation is ATOVAQUONE-PROG TAB 250/100MG 100 with 16 shipments worth $786.9K.
Regulatory Requirements: Exporting Atovaquone to Key Markets
What Glenmark Pharmaceuticals Limited must comply with to export Atovaquone to its top destination countries
United States — FDA
Approval Process
ANDA (Abbreviated New Drug Application) for generics. Indian manufacturing site must pass FDA pre-approval inspection. Drug Master File (DMF) required for APIs.
Timeline: 10–18 months for ANDA approval
GMP & Export Requirements
FDA cGMP compliance (21 CFR 210/211); facility inspection by FDA
Drug Listing with FDA; Export Certificate from CDSCO India; Import Alert screening via FDA PREDICT system
Note: Subject to FDA Import Alerts. Open Form 483 observations can block all exports from a facility.
Germany — BfArM/EMA
Approval Process
Marketing Authorisation via Decentralized or Mutual Recognition Procedure under EU Directive 2001/83/EC. CTD Module 1–5 dossier required.
Timeline: 12–18 months via Decentralized Procedure
GMP & Export Requirements
EU GMP (EudraLex Vol. 4); GMP certificate from EU competent authority; WHO Prequalification accepted as supporting evidence
Certificate of Pharmaceutical Product (CPP) from CDSCO; Written Confirmation for API export per EU requirements; EU FMD serialization mandatory
Note: Indian manufacturers must hold EU GMP certificate. EU Falsified Medicines Directive (FMD) serialization and tamper-evident packaging mandatory.
Canada — HC
Approval Process
ANDS (Abbreviated New Drug Submission) referencing Canadian Reference Product. Comparative bioavailability study required.
Timeline: 12–18 months
GMP & Export Requirements
Health Canada GMP (GUI-0001); Drug Establishment Licence (DEL) inspection
Drug Identification Number (DIN) for each product; Certificate of Pharmaceutical Product from CDSCO
Note: Subject to Good Import Practices and annual C.01.014.6 review.
Regulatory information is provided for general reference based on publicly available guidelines. Requirements vary by formulation, dosage form, and therapeutic classification. Exporters should consult qualified regulatory affairs professionals for case-specific guidance.
How Does Glenmark Pharmaceuticals Limited Compare to Nearest Atovaquone Exporters?
Exporters ranked immediately above and below #2 by export value
| # | Supplier | Export Value | Shipments | Countries | Avg/Shipment |
|---|---|---|---|---|---|
| 2 | GLENMARK PHARMACEUTICALS LIMITED ★ | $8.8M | 177 | 11 | $50.0K |
| 3 | HETERO LABS LIMITED | $6.8M | 137 | 4 | $50.0K |
| 1 | MYLAN LABORATORIES LIMITED | $2.9M | 58 | 5 | $50.0K |
Glenmark Pharmaceuticals Limited ranks #2 among 17 Indian Atovaquone exporters. Average shipment value of $50.0K compared to the market average of $1.2M. The closest competitors by value are HETERO LABS LIMITED and MYLAN LABORATORIES LIMITED.
Which Indian Ports Ship Atovaquone Exports?
| Port | Shipments | % Share |
|---|---|---|
| SAHAR AIR | 80 | 18.3% |
| SAHAR AIR CARGO ACC (INBOM4) | 62 | 14.2% |
| HYDERABAD ICD (INSNF6) | 42 | 9.6% |
| NHAVA SHEVA SEA (INNSA1) | 33 | 7.6% |
| HYDERABAD AIR | 27 | 6.2% |
| JNPT | 26 | 5.9% |
| DELHI AIR | 26 | 5.9% |
| DELHI AIR CARGO ACC (INDEL4) | 22 | 5.0% |
What Other Antimalarial & Antiparasitic Products Does Glenmark Pharmaceuticals Limited Export?
Glenmark Pharmaceuticals Limited also exports these antimalarial & antiparasitic products. Each links to the detailed product page.
Geopolitical & Trade Policy Impact on Glenmark Pharmaceuticals Limited's Atovaquone Exports
Glenmark's export operations are influenced by various geopolitical factors. The Israel-Iran tensions have led to disruptions in Red Sea shipping routes, causing increased freight costs and extended transit times. These challenges are particularly impactful for time-sensitive pharmaceutical shipments, necessitating strategic adjustments in logistics and supply chain management. (pharmaceuticalcommerce.com)
Conversely, the US-China trade tensions have opened avenues for Indian pharmaceutical companies like Glenmark to expand their footprint in the US market. The shifting trade dynamics have prompted US importers to seek alternative suppliers, presenting growth opportunities for Indian exporters.
The recent India-European Union Free Trade Agreement (FTA) is poised to benefit Glenmark by eliminating tariffs on pharmaceutical exports to the EU. This development enhances the company's competitiveness in the European market, potentially boosting export volumes and revenue streams. (en.wikipedia.org)
Glenmark Pharmaceuticals Limited — Regulatory Compliance & Quality Standards
Compliance with international regulatory standards is paramount for Glenmark's export success. The company has consistently adhered to guidelines set by the US FDA, WHO, and EU GMP, ensuring the quality and safety of its products. Notably, Glenmark's manufacturing facilities have undergone rigorous inspections, reflecting its commitment to maintaining high-quality standards.
The evolving regulatory landscape, including the EU's Falsified Medicines Directive, necessitates continuous adaptation. Glenmark's proactive approach to compliance positions it well to navigate these changes, thereby sustaining its market access and reputation.
About Glenmark Pharmaceuticals Limited
Glenmark Pharmaceuticals Limited exports 28 products worth $205.5M. Beyond Atovaquone, top products include Rosuvastatin, Omeprazole, Gabapentin, Ondansetron, Naproxen. View the complete Glenmark Pharmaceuticals Limited profile for full portfolio analysis.
Market Intelligence
Latest developments and market context
Detailed market intelligence for Atovaquone — including regulatory updates, trade policy changes, and competitive landscape analysis — will be available in an upcoming update. This section will feature AI-researched insights from verified industry sources, government notifications, and market reports.
Official References & Regulatory Resources
- CDSCO India
- Pharmexcil
- IBEF — India Pharma Industry
- Ministry of Commerce — Pharma Exports
- India Trade Statistics (DGFT)
Verify manufacturer licensing and export certifications with the official agencies above.
Research Methodology & Data Transparency
Suresh Sormare
Verified AuthorPharmaceutical Export-Import Analyst & Trade Intelligence Expert
Suresh Sormare is a pharmaceutical export-import analyst with deep expertise in Indian Customs (DGFT) data, HS code classification, and global pharmaceutical supply chains. His analysis covers 10M+ shipment records across 150+ countries and is used by manufacturers, procurement agencies, and trade consultants worldwide. Suresh specializes in identifying verified suppliers and buyers from customs records, mapping bilateral pharmaceutical trade corridors, analyzing tariff structures and regulatory frameworks across 170+ destination markets, and benchmarking competitive positioning for finished pharmaceutical formulations. His methodology combines granular customs transaction data with regulatory intelligence from FDA, EMA, WHO, CDSCO, and 40+ national drug authorities to deliver actionable trade insights for the pharmaceutical formulations sector.
linkedin.com/in/sureshsormarePrimary Data Source
All trade data is sourced from Indian Customs (DGFT) official shipping bill records — the authoritative government database for India's pharmaceutical trade. Each verified record contains exporter name, consignee (buyer) name, detailed product description, quantity, declared FOB value (USD), port of loading, destination country, and shipment date.
Analysis Methodology
- 1.Product Matching: Atovaquone shipments identified using fuzzy matching on DGFT product description fields, validated against Indian Pharmacopoeia nomenclature.
- 2.Supplier Identification: Glenmark Pharmaceuticals Limited matched across shipments using name normalization, accounting for company name formatting variations.
- 3.Statistical Normalization: Shipment values are statistically normalized to ensure accurate market share representation. This removes the impact of unusually large one-off transactions that could distort company rankings.
- 4.Verified Records: This page is backed by 185 individual customs records matching Glenmark Pharmaceuticals Limited exporting Atovaquone, covering 114 formulations to 11 countries via 28 buyers.
Government-Sourced Data
Official DGFT customs records
Transparent Methodology
Calculations fully disclosed above
Global Coverage
Exports to 21+ countries, 71+ buyers
Expert-Reviewed
Analyzed by pharmaceutical trade specialists
Get Atovaquone Export Data from Glenmark Pharmaceuticals Limited
Access shipment-level details, pricing data, buyer connections, and competitive analysis for Glenmark Pharmaceuticals Limited's Atovaquone exports. TransData Nexus provides verified Indian Customs (DGFT) data trusted by pharmaceutical trade professionals worldwide.
Glenmark Pharmaceuticals Limited
Full Company Profile →
28 products · $205.5M total trade · 14 categories
Atovaquone Stats
Company Overview
Top Products by Glenmark Pharmaceuticals Limited
Related Analysis
Need Detailed Export Data?
Access shipment-level records, pricing trends, and buyer contacts for Glenmark Pharmaceuticals Limited.
Request DemoView Pricing →Data Source
Trade data sourced from Indian Customs (DGFT) export shipment records. Values represent FOB export value in USD. Market share calculated relative to total Indian pharmaceutical exports for Atovaquone. For current shipment-level data, contact TransData Nexus.